DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 - 3 Years-Old

Stock Information for DBV Technologies S.A.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About DBV Technologies S.A.

DBV Technologies Announces Financing of up to $306.9 Million (Euro284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4-7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study
Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2024
DBV Technologies Announces Plan to Implement ADS Ratio Change
DBV Technologies Reports Third Quarter 2024 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.